CHARIOTEER - Trademark Details
Status: 706 - A Section 71 declaration has been accepted
Image for trademark with serial number 79066733
Serial Number
79066733
Registration Number
3722653
Word Mark
CHARIOTEER
Status
706 - A Section 71 declaration has been accepted
Status Date
2019-07-30
Filing Date
2008-12-12
Registration Number
3722653
Registration Date
2009-12-08
Mark Drawing
3000 - Illustration: Drawing or design which also includes word(s)/ letter(s)/number(s) Typeset
Design Searches
260102, 260121, 261701, 261706, 261709, 280103 - Plain single line circles. Circles that are totally or partially shaded. Straight line(s), band(s) or bar(s). Diagonal line(s), band(s) or bar(s). Curved line(s), band(s) or bar(s). Inscriptions in Chinese, Japanese, Korean, Vietnamese or other Asian characters.
Published for Opposition Date
2009-09-22
Law Office Assigned Location Code
M70
Employee Name
LEE, DEBRA ANN
Statements
Indication of Colors claimed
Color is not claimed as a feature of the mark.
Description of Mark
The mark consists of a stylized wheel and axle with two Chinese characters and the wording "CHARIOTEER" appearing beneath the design.
Goods and Services
Antipyretyc, analgesic and anti-inflammatory active pharmaceutical ingredient, namely, naproxen, naproxen sodium, naproxen celecoxib, nimesulide, aceclofenac, sulindac, ibuprofen, fenoprofen, ketoprofen, celecoxib, nimesulide, aceclofenac; anti-inflammatory active pharmaceutical ingredient, namely, naproxen nitroxyalkylesters; antipyretic and analgesic active pharmaceutical ingredient, namely, aspirin, acetaminophen, propyphenazone; antipyretic and analgesic, antithrombotic active pharmaceutical ingredient, namely, indomethacin; analgesic active pharmaceutical ingredient, namely, eptazocine, ketorolac tromethamine; antipyretic, analgesic active pharmaceutical ingredient, namely, propyphenazone; anti-inflammatory and anti-virus active pharmaceutical ingredient, namely, amantadine hydrochloride; treating rheumatoid arthritis active pharmaceutical ingredient, namely, flurbiprofen, meloxicam, phenylbutazone; anti-platelet aggregation active pharmaceutical ingredient, namely, clopidogrel hydrogen sulfate; anti-platelet drugs active pharmaceutical ingredient, namely, prasugrel; anti-cancer active pharmaceutical ingredient, namely, topotecan hydrochloride, ifosfamide, mesna, irinotecan, camptothecin, 7-ethyl-10-hydrol-camptothecin, docetaxel; treating iodine deficiency active pharmaceutical ingredient, namely, iodine; anti-goitre expectoration and active pharmaceutical ingredient, namely, potassium iodide; treating supraventricular arrhythmia, typical angina and variant angina active pharmaceutical ingredient, namely, diltiazem; anti-hepatitis B virus active pharmaceutical ingredient, namely, adefovir dipivoxil, lamivudine, telbivudine, clevudine; anti-urogenital system disease active pharmaceutical ingredient, namely, phenazopyridine hydrochloride; anti-virus active pharmaceutical ingredient, namely, acyclovir, acyclovir sodium, penciclovir, zidovudine, ganciclovir, ganciclovir sodium, famciclovir, valaciclovir hydrochloride, valganciclovir hydrochloride, ribavirin, 6-deoxyacyclovir, polyinosinic polycytidylic acid, interferons, adenine, farmivisen, docosanol, zanamvir, oseltamivir, indinavir, ritonavir, nelfinavir, delavirdine, efavirenz, ainprenavir, lopinavir, cidofovir, imiquimod, didanosine, foscarnet sodium, penciclovir sodium, stavudine, abacavir, tenofovir disoproxil, emdtricitabine, brivudine, amprenavir, rimantadine; expectorant active pharmaceutical ingredient, namely, fudosteine, carbocisteine; anti-hypertension active pharmaceutical ingredient, namely, valsartan, losartan, irbesartan, tasosartan, candesartan, telmisartan, eprosartan, olmesartan; anxiolytic active pharmaceutical ingredient, namely, brofoxine; treating coronary heart disease active pharmaceutical ingredient, namely, dipyridamole; immunosuppressive active pharmaceutical ingredient, namely, tacrolimus; immunosuppressive agents active pharmaceutical ingredient, namely, sirolimus; treating cardiac and cerebrovascular disease active pharmaceutical ingredient, namely, nicergoline; treating coronary heart disease active pharmaceutical ingredient, namely, isosorbide mononitrate; anti-obesity active pharmaceutical ingredient, namely, orlistat; antipsychotic active pharmaceutical ingredient, namely, perazine maleate, carisoprodol; anti-leprosy disease active pharmaceutical ingredient, namely, thalidomide; anti-vitamin deficiency active pharmaceutical ingredient, namely, folic acid, dexpanthenol; anti-megaloblastic anemia active pharmaceutical ingredient, namely, calcium levofolinate; antithrombotic active pharmaceutical ingredient, namely, ticlopidine hydrochloride; anti-rejection active pharmaceutical ingredient, namely, rapamycin, mizoribine, mycophenolic acid, mycophenolate mofetil, mycophenolate sodium, clarithromycin, daptomycin, mupirocin, ertapenem, doripenem, biapenem, meropenem, imipenem, faropenem, aztreonam, benflumetol, mupirocin, caspofungin; treating diabetes mellitus active pharmaceutical ingredient, namely, metformin, voglibose; antioxidant, treatment heart disease and anti-hypertension active pharmaceutical ingredient, namely, coenzyme Q10; treating brain edema and glaucoma active pharmaceutical ingredient, namely, isosorbide; anti-aids active pharmaceutical ingredient, namely, nevirapine
Transliteration Statement
The non-Latin characters in the mark transliterate to "CHE TOU" and this means "charioteer" and "the front of a vehicle" in English.
Classification Information
International Class
005 - Pharmaceutical, veterinary and sanitary preparations; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. - Pharmaceutical, veterinary and sanitary preparations; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes
006, 018, 044, 046, 051, 052
Class Status Code
6 - Active
Class Status Date
2009-04-17
Primary Code
005
Current Trademark Owners
Party Type
30 - Original Registrant
Address
Please log in with your Justia account to see this address.
Trademark Owner History
Party Type
10 - Original Applicant
Address
Please log in with your Justia account to see this address.
Party Type
30 - Original Registrant
Address
Please log in with your Justia account to see this address.
Party Type
20 - Owner at Publication
Address
Please log in with your Justia account to see this address.
Correspondences
Name
ZHEJIANG CHARIOTEER; PHARMACEUTICAL CO.L
Address
Please log in with your Justia account to see this address.
International Registrations
International Registration Number
0997289
International Registration Date
2008-12-12
International Publication Date
2009-04-23
International Renewal Date
2028-12-12
Auto Protection Date
2010-10-16
International Status
001 - Request for extension of protection established
International Status Date
2009-04-16
Priority Claimed In
False
First Refusal In
True
Trademark Events
Event DateEvent Description
2009-04-16SN ASSIGNED FOR SECT 66A APPL FROM IB
2009-04-17NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
2009-04-17ASSIGNED TO EXAMINER
2009-04-21APPLICATION FILING RECEIPT MAILED
2009-04-25NON-FINAL ACTION WRITTEN
2009-04-26NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
2009-04-27REFUSAL PROCESSED BY MPU
2009-04-27NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
2009-05-22REFUSAL PROCESSED BY IB
2009-07-15TEAS RESPONSE TO OFFICE ACTION RECEIVED
2009-07-15CORRESPONDENCE RECEIVED IN LAW OFFICE
2009-07-20TEAS/EMAIL CORRESPONDENCE ENTERED
2009-08-11APPROVED FOR PUB - PRINCIPAL REGISTER
2009-08-18ASSIGNED TO LIE
2009-08-18LAW OFFICE PUBLICATION REVIEW COMPLETED
2009-09-02NOTICE OF PUBLICATION
2009-09-22PUBLISHED FOR OPPOSITION
2009-12-08REGISTERED-PRINCIPAL REGISTER
2010-03-09FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
2010-04-01FINAL DISPOSITION PROCESSED
2010-04-01FINAL DISPOSITION NOTICE SENT TO IB
2013-01-30FINAL DECISION TRANSACTION PROCESSED BY IB
2014-12-11TEAS CHANGE OF CORRESPONDENCE RECEIVED
2014-12-11TEAS SECTION 71 RECEIVED
2015-01-15CASE ASSIGNED TO POST REGISTRATION PARALEGAL
2015-01-15REGISTERED-SEC.71 ACCEPTED
2015-01-15NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED
2018-12-08COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED
2018-12-28INTERNATIONAL REGISTRATION RENEWED
2019-07-26TEAS SECTION 71 RECEIVED
2019-07-26TEAS CHANGE OF CORRESPONDENCE RECEIVED
2019-07-30REGISTERED-SEC.71 ACCEPTED
2019-07-30NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED